Experienced in Pure Red Cell Aplasia

Dr. Sonali S. Chaudhury

Pediatric Hematology Oncology
225 E. Chicago Ave., 
Chicago, IL 
Clinical Trials:Currently Recruiting for 1 Trial
23 Years of Experience
Experienced in Pure Red Cell Aplasia
225 E. Chicago Ave., 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sonali Chaudhury is a Pediatric Hematologist Oncology provider in Chicago, Illinois. Dr. Chaudhury has been practicing medicine for over 23 years and is rated as an Experienced provider by MediFind in the treatment of Pure Red Cell Aplasia. Her top areas of expertise are Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), Severe Combined Immunodeficiency (SCID), Sickle Cell Disease, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 73 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in IL
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

225 E. Chicago Ave., Chicago, IL 60611

Additional Areas of Focus

Dr. Chaudhury has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Reduced-Intensity Preparatory Regime
A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Reduced-Intensity Preparatory Regime
Enrollment Status: Recruiting
Publish Date: July 22, 2024
Intervention Type: Drug
Study Drugs: Stratum 1, Strata 2, 3, or 4, GVHD Regimen
Study Phase: Phase 1/Phase 2
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Biological
Study Drug: CTL019
Study Phase: Phase 2
Long Term Outcomes in β Thalassemia Major - Comparing Late Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation and Standard Supportive Care
Long Term Outcomes in β Thalassemia Major - Comparing Late Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation and Standard Supportive Care
Enrollment Status: Completed
Publish Date: February 11, 2025
Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial
Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial
Enrollment Status: Completed
Publish Date: July 17, 2024
Intervention Type: Drug
Study Drug: Abatacept
Study Phase: Phase 2
Abatacept for Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease: a Sickle Transplant Alliance for Research Trial
Abatacept for Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease: a Sickle Transplant Alliance for Research Trial
Enrollment Status: Completed
Publish Date: June 13, 2024
Intervention Type: Drug, Procedure
Study Drugs: Diphenhydramine, Acetaminophen, Methylprednisolone, Meperidine, Alemtuzumab, Thymoglobulin, Fludarabine, Melphalan, Thiotepa, Cyclosporine, Tacrolimus, Methotrexate, Abatacept, Sirolimus, Mycophenolate Mofetil
Study Phase: Phase 1
Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team) - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease
Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team) - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2023
A Phase II, Open Label, Multi-center Trial to Determine the Efficacy and Safety of Tisagenlecleucel Re-infusion in Pediatric and Adolescent Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia Experiencing Loss of B Cell Aplasia
A Phase II, Open Label, Multi-center Trial to Determine the Efficacy and Safety of Tisagenlecleucel Re-infusion in Pediatric and Adolescent Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia Experiencing Loss of B Cell Aplasia
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Biological
Study Drug: Tisagenlecleucel
Study Phase: Phase 2
A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Enrollment Status: Completed
Publish Date: March 17, 2022
Intervention Type: Drug
Study Phase: Phase 3
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Enrollment Status: Unknown
Publish Date: September 02, 2021
View 8 Less Clinical Trials

73 Total Publications

Management Practices of CAR T-cell-Related Inflammatory Toxicities: A Survey of Pediatric CAR T-cell Providers.
Management Practices of CAR T-cell-Related Inflammatory Toxicities: A Survey of Pediatric CAR T-cell Providers.
Journal: Transplantation and cellular therapy
Published: July 06, 2025
Similar Doctors
Experienced in Pure Red Cell Aplasia
Dr. Sherif M. Badawy
Pediatric Hematology Oncology
Experienced in Pure Red Cell Aplasia
Dr. Sherif M. Badawy
Pediatric Hematology Oncology

Lurie Children's Medical Group Inc.

225 E Chicago Ave, Box 118, 
Chicago, IL 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances

Sherif Badawy is a Pediatric Hematologist Oncology provider in Chicago, Illinois. Dr. Badawy is rated as an Elite provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Bone Marrow Transplant, and Bone Graft.

Experienced in Pure Red Cell Aplasia
Dr. Ammar Hayani
Pediatric Hematology Oncology
Experienced in Pure Red Cell Aplasia
Dr. Ammar Hayani
Pediatric Hematology Oncology
25 N Winfield Rd, 
Winfield, IL 
 (27.5 miles away)
630-933-4291
Languages Spoken:
English
See accepted insurances

Ammar Hayani is a Pediatric Hematologist Oncology provider in Winfield, Illinois. Dr. Hayani is rated as an Advanced provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Hereditary Spherocytosis, Congenital Hemolytic Anemia, Hemolytic Anemia, and Acute Lymphoblastic Leukemia (ALL).

Experienced in Pure Red Cell Aplasia
Dr. Jennifer A. Schneiderman
Pediatric Hematology Oncology
Experienced in Pure Red Cell Aplasia
Dr. Jennifer A. Schneiderman
Pediatric Hematology Oncology
2300 N Childrens Plz # 30, 
Chicago, IL 
 (2.4 miles away)
773-880-4000
Languages Spoken:
English
See accepted insurances

Jennifer Schneiderman is a Pediatric Hematologist Oncology provider in Chicago, Illinois. Dr. Schneiderman is rated as an Advanced provider by MediFind in the treatment of Pure Red Cell Aplasia. Her top areas of expertise are Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Neuroblastoma, Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chaudhury's expertise for a condition
ConditionClose
    View All 15 Advanced Conditions
    View All 22 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile